Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 163 of the 166 references it cites were found in a registry or an index.

Tumour burden and efficacy of immune-checkpoint inhibitors

Abstract

Accumulating evidence suggests that a high tumour burden has a negative effect on anticancer immunity. The concept of tumour burden, simply defined as the total amount of cancer in the body, in contrast to molecular tumour burden, is often poorly understood by the wider medical community; nonetheless, a possible role exists in defining the optimal treatment strategy for many patients. Historically, tumour burden has been assessed using imaging. In particular, CT scans have been used to evaluate both the number and size of metastases as well as the number of organs involved. These methods are now often complemented by metabolic tumour burden, measured using the more recently developed 2-deoxy-2-[ 18 F]-fluoro-D-glucose (FDG)-PET/CT. Serum-based biomarkers, such as lactate dehydrogenase, can also reflect tumour burden and are often also correlated with a poor response to immune-checkpoint inhibitors. Other circulating markers (such as circulating free tumour DNA and/or circulating tumour cells) are also attracting research interest as surrogate markers of tumour burden. In this Review, we summarize evidence supporting the utility of tumour burden as a biomarker to guide the use of immune-checkpoint inhibitors. We also describe data and provide perspective on the various tools used for tumour burden assessment, with a particular emphasis on future therapeutic strategies that might address the issue of inferior outcomes among patients with cancer with a high tumour burden.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41571-021-00564-3

Cites

163 of 163 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 166 references

Research works printed but not linked: 1

  1. Kinoshita, T., Ito, H. & Miki, C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85, 2526–2531 (1999). · DOI

Cited by

See all 368

Metadata

Authors
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B.
Affiliations
  • Institut Gustave Roussy (FR)
  • Inserm (FR)
  • Hôpital Marie Lannelongue (FR)
  • Université Paris-Saclay (FR)
Corresponding author
Besse, Benjamin
Venue
Nature Reviews Clinical Oncology
Published
2021-10-12
Volume
19
Issue
2
Pages
75-90
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W3206266376
Cited by
350
References
166
Citations by year
2026: 48 · 2025: 97 · 2024: 98 · 2023: 63 · 2022: 44
FWCI
6.30
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
tumor burden, immune checkpoint inhibitors, FDG PET/CT, lactate dehydrogenase, circulating tumor DNA, circulating tumor cells, tumour biomarkers, treatment response prediction, tumor immunology, metastasis
MeSH terms
Immune Checkpoint Inhibitors, Humans, Neoplasms, Prognosis, Tumor Burden

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumour burden and efficacy of immune-checkpoint inhibitors. https://app.cochat.ai/papers/10.1038/s41571-021-00564-3
The paper
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022). Tumour burden and efficacy of immune-checkpoint inhibitors. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-021-00564-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.